The War on Cancer
President Nixon declared war on cancer in 1971. Fifty years later, we're still fighting. $2.1 trillion has been spent globally. Progress is real. Cure is not.
Cancer is not one disease. It's hundreds. Some respond to treatment. Some don't. Survival rates have improved for many cancers. Prevention remains elusive. A "cure for cancer" was never realistic. Cures for specific cancers are the only metric that matters.
Progress by Cancer Type
Cancer research shows measurable progress in survival rates for many cancers. This is real. This matters. This is not the same as a cure.
| Cancer Type | 1975 5-Year Survival | 2023 5-Year Survival | Improvement |
|---|---|---|---|
| Melanoma | 81% | 93% | +12% |
| Breast Cancer (Female) | 75% | 91% | +16% |
| Prostate Cancer | 69% | 98% | +29% |
| Colorectal Cancer | 51% | 67% | +16% |
| Lung Cancer | 13% | 23% | +10% |
| Pancreatic Cancer | 3% | 11% | +8% |
What This Means: For many cancers, detection and treatment have improved dramatically. Patients live longer. More patients survive past five years. This is progress. This is not prevention. This is not a cure. This is management of a disease that still kills 10 million people annually worldwide.
The Promise vs. Reality Pattern
Current Research Status
Cancer research is more productive than ever by one measure: drug approvals. The FDA approves 30--50 new cancer therapies annually. Each extends survival. Few cure disease. The innovation pipeline is robust. The cure rate is not.
Sources & Methodology
Data compiled from NIH, peer-reviewed sources, and public records.
Primary Sources
- National Institutes of Health -- Cancer Research Funding (RePORT Database)
- American Cancer Society -- Cancer Statistics Annual Reports (2023)
- FDA Center for Drug Evaluation -- Oncology Approvals Database (2020--2024)
- ClinicalTrials.gov -- Cancer Active Trials (2,400+ trials)
- SEER Program (Surveillance, Epidemiology, and End Results) -- 5-Year Survival Trends
- Tufts Center for the Study of Drug Development -- Cancer Trial Success Rates
- Nature Reviews Cancer -- Immunotherapy Progress and Limitations (2023)